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ANKH = human homologue of the mouse progressive ankylosis (ank) gene; COMP = cartilage oligomeric matrix protein; CMP = cartilage matrix
protein; IL-1 = interleukin-1; MED = multiple epiphyseal dysplasia; OA = osteoarthritis; PGOA = primary generalized osteoarthritis; SED = spondy-
loepiphyseal dysplasia; TGFβ1 = transforming growth factor beta 1.
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Introduction
Osteoarthritis (OA), the most common form of arthritis, is
no longer regarded as a simple consequence of age-
related cartilage degeneration, but rather is regarded as
the result of an active process, which may be regenerative
rather than degenerative in nature. Furthermore, OA is
probably not a single disorder, but rather a group of over-
lapping distinct diseases. These diseases are the conse-
quences of mechanical or biological events that
destabilize the normal coupling of synthesis and degrada-
tion of extracellular matrix in articular cartilage and sub-
chondral bone. It is commonly assumed that multiple
factors, including genetic and developmental, metabolic,
and traumatic factors can trigger osteoarthritic disease. At
later stages, the disease is characterized by molecular,
morphological, and biomechanical changes which lead to
softening, fibrillation, ulceration, and loss of articular carti-
lage, eburnation of subchondral bone, osteophytes, and
subchondral bone cysts [1]. Extracellular matrix molecules
play a critical role in the normal maintenance of articular
cartilage structure, regulation of chondrocyte proliferation
and gene expression, and cartilage aging and repair, and
they are important in the pathophysiology of OA.
Articular cartilage is composed of an extracellular matrix
designed to resist tensile and compressive forces and
provide a smooth surface to permit low-friction movement in
joints. These properties are the result of the interactions
between a large number of proteins and proteoglycans
present in the matrix (Fig. 1). Many of these components are
listed in Table 1; this list, which is by no means exhaustive,
includes those components that have been studied the
most. Type II collagen is the major collagenous component,
but collagens III, VI, IX, X, XI, XII, and XIV also contribute to
the mature cartilage matrix. Noncollagenous components
include large amounts of the hyaluronate-binding proteogly-
can aggrecan and its associated link protein, as well as
other collagen-binding proteoglycans, such as decorin,
fibromodulin, and lumican, and proteins such as PRELP
(proline/arginine-rich and leucine-rich repeat protein) and
cartilage oligomeric matrix protein (COMP) [2]. The struc-
ture and abundance of these components change with age
because of a combination of changes in both synthetic and
degradative events [3]. The effects of mutations in the
genes encoding these structural components of the matrix
have provided insight into the function of the individual gene
products in the pathogenesis of OA.
Osteoarthritis (OA), one of the most common age-related chronic disorders of articular cartilage, joints,
and bone tissue, represents a major public health problem. Genetic studies have identified multiple
gene variations associated with an increased risk of OA. These findings suggest that there is a large
genetic component to OA and that the disorder belongs in the multigenetic, multifactorial class of
genetic diseases. Studies of chondrodysplasias and associated hereditary OA have provided a better
understanding of the role of structural genes in the maintenance and repair of articular cartilage, in the
regulation of chondrocyte proliferation and gene expression, and in the pathogenesis of OA.
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Large genetic component in osteoarthritis
Twin studies and cohort studies have highlighted a sur-
prisingly large genetic component to OA [4–6]. These
findings have prompted the search for predisposing genes
using parametric linkage analyses of rare families in which
OA segregates as a Mendelian trait, model-free linkage
analysis of affected sibling pairs, and association analysis
of known candidate genes. Linkage studies have high-
lighted chromosomes 1, 2, 4, 6, 7, 9,11-13,16,19, and X
as potential chromosomes with OA susceptibility genes
[7–15]. Chromosomes 2,4,7,11, and 16 have been identi-
fied in multiple genome-wide scans and are therefore the
most likely candidates. In addition, association analysis of
candidate genes suggests that COL2A1 (chromo-
some 12), COL1A1 (chromosome 17), COL9A1 (chromo-
some 6), COL11A2 (chromosome 6), CMP (cartilage
matrix protein) (chromosome 1), VDR (vitamin D receptor)
(chromosome 12), ER (estrogen receptor) (chromo-
some 6), IGF-1 (insulin-like growth factor 1)
(chromosome 12), aggrecan (chromosome 15), and
TGFβ1 (chromosome 19) may represent ‘osteoarthritic
genes’ [16–25]. These findings support the notion that
there is a large genetic component to OA and that the
disease can be classified as a multigenetic, multifactorial
genetic disease.
Hereditary osteoarthritis
Mutations in genes encoding molecules expressed in
cartilagenous tissue lead to hereditary OA [26,27]. The
phenotypic spectrum is quite broad, encompassing very
severe forms, which become manifest early in life, to mild
disorders, which become clinically evident only late in life.
Hereditary OA can be subdivided into conditions such as
early-onset OA associated with an underlying familial
osteochondrodysplasia, conditions associated with meta-
bolic joint diseases including crystal-associated
arthropathies (familial calcium pyrophosphate deposition
disease and familial hydroxyapatite deposition disease),
and primary generalized osteoarthritis (PGOA) with mild
dysplasia [26,27]. The familial osteochondrodysplasias
represent a heterogeneous group of disorders character-
ized by abnormalities in the development and growth of
articular and growth-plate cartilages. The term ‘chon-
drodysplastic rheumatism’ has been used to refer to these
forms of OA. They include the type II and type XI col-
lagenopathies, the multiple epiphyseal dysplasias (MEDs),
and the metaphyseal chondrodysplasias. They are usually
inherited as fully penetrant autosomal dominant disorders.
The expression of the OA phenotype occurs early in life,
with distinct radiographic changes that are different from
the nondysplastic forms of inherited OA.
Figure 1
Diagram showing the collagen components (collagens II, IX and XI) of cartilage fibril (top) and the association between the fibril and
noncollagenous components of cartilage, such as matrilin-3, COMP, and complexes of aggrecan, link protein and hyaluronan (bottom). COMP,
cartilage oligomeric matrix protein.
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Families with PGOA without dysplasia exhibit a higher inci-
dence of OA than is seen in the general population, with
premature development of Heberden’s and Bouchard’s
nodes and cartilage degeneration at multiple joints [28].
Early studies showed that first-degree relatives of PGOA
probands were twice as likely to have radiographically
visible generalized disease as a control population [29].
Structural genes responsible for familial osteochondrodys-
plasias were initially considered strong candidates also for
PGOA, on the basis that mutations in such genes could
cause a spectrum of phenotypes from the most severe
chondrodysplasia with associated OA to a very mild phe-
notype of OA only. For example, several point mutations in
the COL2A1 gene have been identified as causes of
severe forms of type II collagenopathies [30], but muta-
tions in this gene are also associated with milder pheno-
types. Thus, mutations in the COL2A1 gene have been
identified in PGOA/late-onset spondyloepiphyseal dyspla-
sia (SED). Mutations resulting in an Arg519Cys substitu-
tion have been identified in several unrelated families with
PGOA and mild chondrodysplasia [31–34]. The
Arg75Cys change has also been identified in a large
family with severe OA, crystal deposition disease, and
late-onset SED [35]. It is likely that the chondrocalcinosis
phenotype in this family is a secondary consequence of
the advanced and severe OA, since structural changes in
the articular cartilage extracellular matrix may predispose
to crystal formation [36,37]. Other heterozygous substitu-
tions in type II collagen, Gly976Ser [38] and Gly493Ser
[39], have been identified in other kindreds with mild dys-
plasia and early-onset OA.
More recent studies have not supported these initial ideas.
In fact, the loci identified on chromosomes 2, 4, 7, 11, and
16 as the most likely candidates for OA susceptibility
genes do not in general correspond to structural matrix
genes. Furthermore, although a recent cohort study found
that a specific COL2A1 haplotype seemed to predispose
to generalized radiographic OA [23], linkage analysis of
14 candidate genes in OA kindreds resulted in the exclu-
sion of 10 important cartilage genes, including COL2A1
[40]. Analysis of 47 families with the phenotype of early-
onset primary OA without an SED phenotype failed to
detect mutations in the COL2A1 in most families, with the
exception of one case [41]. Other studies using multi-
allelic polymorphism and genetic analysis of sibling pairs
failed to identify COL2A1 as the disease locus in families
with features of PGOA in the absence of SED [42,43].
Therefore, a majority of patients with PGOA are likely to
have mutations in genes other than COL2A1 and other
structural matrix genes.
Familial osteochondrodysplasias
OA associated with familial osteochondrodysplasias
caused by mutations in (mostly) structural cartilage matrix
genes represents a subset of secondary OA. Studies of
this form of OA, however, are important as they provide
insights into the molecular processes that lead to articular
cartilage destruction in all forms of OA.
Table 2 summarizes genetic defects in structural macro-
molecules of cartilage that lead to alterations in chondro-
genesis, skeletal malformations, reduced skeletal function,
or predisposition to injury and OA. Mutations in type II col-
lagen cause a spectrum of diseases known as ‘type II col-
lagenopathies’. The severity ranges from developmental
lethality (achondrogenesis type II, hypochondrogenesis),
to moderately severe dwarphism (SED, Kniest dysplasia),
to normal stature with premature OA. In the case of lethal
mutations with absence of type II collagen, some embry-
onic cartilage develops with type I collagen susbstituted
for type II collagen, and bone is formed [44]. Mutations
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Table 1
The most-studied components of cartilage matrix
Collagens
Types IIa and IIb
Type III
Type VI
Type IX
Type X
Type XI
Type XII
Type XIV
Proteoglycans
Aggrecan
Versican
Link protein
Biglycan (DS-PGI)
Decorin (DS-PGII)
Epiphycan (DS-PGIII)
Fibromodulin
Lumican
Perlecan
Proteoglycan 4
Noncollagenous proteins
COMP (cartilage oligomeric matrix protein; thrombospondin-5)
CMP (cartilage matrix protein; matrilin-1)
Matrilin-3
CILP (cartilage intermediate layer protein)
Fibronectin
PRELP (proline/arginine-rich and leucine-rich repeat protein)
Chondroadherin
Fibrillin
Tenascin-C
Elastin
MGP (matrix Gla protein)
Chondromodulin-I
Chondromodulin-II
CD-RAP (cartilage-derived retinoic acid-sensitive protein)
ANKH
Matrix metalloproteinases and related enxymes
Tissue inhibitors of metalloproteinases340
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Table 2
Structural gene mutations in cartilage that result in abnormal cartilage matrix
OMIM# Gene name Gene symbol  Diseases and disorders
12140 Collagen, type II α1 COL2A1 Achondrogenesis, type II
Achondrogenesis–hypochondrogenesis, type II
Epiphyseal dysplasia, multiple, with myopia and conductive deafness
Hypochondrogenesis
Kniest dysplasia
Osteoarthritis with mild dysplasia
Spondyloepiphyseal dysplasia, congenital type
Spondyloepiphyseal dysplasia, Namaqualand type
Spondyloepiphyseal dysplasia, Strudwick type
Spondyloepiphyseal dysplasia, various types
Spondyloepiphyseal dysplasia with precocious OA
Spondyloperipheral dysplasia
Stickler syndrome, type I
Wagner syndrome
120180 Collagen, type III α1 COL3A1 Arterial and aortic aneurysm
Ehlers–Danlos syndrome, types III and IV
120220 Collagen, type VI α1 COL6A1 Bethlem myopathy
120240 Collagen, type VI α2 COL6A2 Bethlem myopathy
Ullrich scleroatonic muscular dystrophy
120250 Collagen, type VI α3 COL6A3 Bethlem myopathy
120210 Collagen, type IX α1 COL9A1 Epiphyseal dysplasia, multiple, type 1
Intervertebral disk disease
120260 Collagen, type IX α2 COL9A2 Epiphyseal dysplasia, multiple, type 2
Intervertebral disk disease
120270 Collagen, type IX α3 COL9A3 Epiphyseal dysplasia, multiple, type 3
Epiphyseal dysplasia, multiple, with myopathy
120110 Collagen, type X α1 COL10A1 Metaphyseal chondrodysplasia, Schmid type
Spondylometaphyseal dysplasia, Japanese type
120260 Collagen, type XI α1 COL11A1 Stickler syndrome, type II
Marshall syndrome
120290 Collagen, type XI α2 COL11A2 Sensorineural deafness, autosomal dominant nonsyndromic
Otospondylomegaepiphyseal dysplasia
Stickler syndrome, type III
Weissenbacher–Zweymuller syndrome
600310 Cartilage oligomeric matrix protein COMP Pseudoachondroplasia
Epiphyseal dysplasia, multiple, Fairbanks type
Epiphyseal dysplasia, multiple, type 1
602109 Matrilin-3 MATN3 Multiple epiphyseal dysplasia, MATN3-related
Epiphyseal dysplasia, multiple, type 5
134797 Fibrillin FBN1 Marfan syndrome, various type
Ectopia lentis, familial
Marfanoid skeletal syndrome
MASS syndrome
Shprintzen–Goldberg syndrome
154870 Matrix γ-carboxyglutamic acid protein MGP Keutel syndrome
142461 Perlecan PLC Schwartz–Jampel syndrome, type 1
Dyssegmental dysplasia, Silverman–Handmaker type
Chondrodystrophic myotonia
222600 Diastrophic dysplasia sulfate transporter DTDST Achondrogenesis IB
Atelostogenesis type II
Diastrophic dysplasia
Epiphyseal dysplasia, multiple type 4
Diastrophic dysplasia, broad-bone–platyspondylic variant
604283 Proteoglycan 4 PRG4 Camptodactyly–arthropathy–coxa vara–pericarditis syndrome
605145 ANK ANKH Craniometaphyseal dysplasia, autosomal dominant
Chondrocalcinosis 2
MASS, mitral valve, aorta, skeleton, skin; OA, osteoarthritis; OMIM, Online Mendelian Inheritance in Man™.341
that cause a moderately severe phenotype (SED, Kniest
dysplasia) generally result from reduced secretion of
type II collagen or reduced content of this collagen in car-
tilage [45–47]. The mildest phenotype (Stickler syndrome,
type I) is caused by premature stop codons resulting in a
null-allele mosaicism [47,48] and is associated with early-
onset OA. Several mouse models of the human type II col-
lagenopathies exist and resemble, depending on the type
and position of the mutation in the COL2A1 gene, a lethal
or a mild human phenotype [49–52].
Mutations in genes for type IX collagen result in MED. This
clinically heterogeneous disorder is characterized by mild
short stature and early-onset OA. In some families, splice-
site mutations in COL9A2 and COL9A3 causing skipping
of exon 3 in α2(IX) and α3(IX) transcripts, respectively
[53–58], are associated with a phenotype characterized
by normal to near-normal height, epiphyseal dysplasia of
several joints during childhood, and OA of the knees in
adulthood. A complex splicing defect of exon 8 and/or
exon 10 in the COL9A1 gene has been identified in other
families [59]. Consistent with these findings, transgenic
mice overexpressing a truncated α1(IX) chain (exerting a
dominant negative effect on assembly of collagen IX mole-
cules) exhibited mild chondrodysplasia and progressive
OA [60]. A similar phenotype was seen in mice carrying
two null alleles for COL9A1 [61]. Type IX collagen mole-
cules are heterotrimers composed of three different
polypeptide chains, α1(IX), α2(IX), and α3(IX), which are
localized on the surface of collagen-II-containing fibrils,
where they get cross-linked to residues within type II colla-
gen molecules and may help stabilize the fibrillar network
[62]. The absence of α1(IX) chains or expression of a
dominant negative form results in the absence or reduced
amounts of collagen IX in cartilage, and this may destabi-
lize the collagen network.
Mutations in the COL11A1 and COL11A2 genes, encod-
ing two of the polypeptide subunits of heterotrimeric colla-
gen XI molecules, give rise to the ‘type XI
collagenopathies’. COL11A1 mutations are associated
with Marshall or Stickler syndrome, characterized by
severe myopia, vitreoretinal degeneration, cleft palate,
midfacial hypoplasia, early-onset OA, and sensorineuronal
hearing loss [63–65]. Extensive genotype–phenotype cor-
relations of patients with Stickler, Stickler-like, or Marshall
syndrome have suggested that null-allele mutations in
COL2A1, encoding the polypeptide chains of collagen II
molecules as well as one of the chains in collagen XI,
cause the typical Stickler phenotype (in which vitreoretinal
degeneration is common and hearing loss is less
common), while splicing mutations in COL11A1 are
responsible for the Marshall syndrome (in which hearing
loss is common and vitreoretinal degeneration is less
common). Patients with glycine substitutions or small dele-
tions in COL11A1 (dominant negative mutations) may
have a mixed phenotype characteristic of both syndromes
[66]. Mutations in COL11A2 are associated with a nonoc-
ular Stickler-like syndrome, otospondylomegaepiphyseal
dysplasia [67–70], Weissenbacher–Zweymuller syn-
drome [69], or nonsyndromic forms of deafness called
DFNA13 (deafness, autosomal dominant nonsyndromic
sensorineural 13) [71]. The explanation for the lack of an
ocular phenotype in these syndromes is the presence of a
unique form of type XI collagen in the vitreous. In cartilage,
collagen XI molecules are heterotrimers of the products of
COL11A1, COL11A2, and COL2A1, but in the vitreous
the COL11A2 chain is replaced by a chain encoded by
COL5A2 [72].
The cho/cho mouse, which is homozygous for a premature
stop codon in the amino-terminal region of α1(XI) collagen
[73], has provided important insights into the role of colla-
gen XI in skeletal development. Heterozygous animals are
relatively unaffected; however, with age they develop
ostearthritis. Homozygous animals die at birth, with short
limbs, short snout, and cleft palate. Growth-plate carti-
lages show a disorganized structure with thick collagen
fibrils. The presence of thick fibrils, providing direct evi-
dence of a role of type XI collagen in regulating fibril diam-
eters, leads to the formation of a large-pore network of
fewer fibrils in cho/cho cartilage than the small-pore
network of thin fibrils found in wild-type cartilage. The
changes in pore size causes the proteoglycan aggregates
to be more loosely entrapped within the mutant matrix than
in the wild type. Mice with Col11a2 null alleles are pheno-
typically comparable with patients who have otospondylo-
megaepiphyseal dysplasia, and their phenotype suggests
that the α2(XI) chain may be required for correct fibril
assembly or lateral association between individual colla-
gen fibrils [74].
Mutations that prevent glycosaminoglycan sulfation of
aggrecan cause chondrodysplastic phenotypes associ-
ated with achondrogenesis, atelostogenesis, diastrophic
dysplasia, and autosomal recessive MED [75]. MED and
pseudoachondroplasia can also be the result of mutations
in COMP, a pentameric molecule belonging to the throm-
bospondin family of matrix molecules and which is local-
ized in the pericellular, territorial matrix of chondrocytes.
The protein contains several repeat domains, including
eight calcium-binding, calmodulin-like repeats. Most
COMP mutations identified in patients with MED or
pseudoachondroplasia are amino acid substitutions that
may disturb calcium binding [76–78]. Mutations in the
gene encoding matrilin-3 [79] can also give an MED clini-
cal phenotype, a phenomenon which provides genetic evi-
dence for a functional interaction between aggrecan,
COMP, collagen IX, and matrilin-3 in cartilage [80].
Mutations in a gene encoding the core protein of a proteo-
glycan associated with articular cartilage cause campto-
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dactyly–arthropathy–coxa vara–pericarditis syndrome [81].
This chondroitin sulfate proteoglycan, called superficial
zone protein, lubricin, or proteoglycan 4, is produced by
the superficial articular chondrocytes and synovial cells. It
is responsible for lubrication of the cartilage surface [82].
The synthesis is impaired in arthritic joints and downregu-
lated by inflammatory cytokines such as IL-1.
Mutation at the progressive ankylosis (ank) locus in the
mouse causes a progressive form of arthritis with deposi-
tion of apatite crystals, formation of bony outgrowths, joint
destruction, and ankylosis [83]. In humans, mutations in
the ank gene, ANKH, have been linked to craniometaphy-
seal dysplasia [84,85]. In addition, analysis of two families
from England and Argentina with familial calcium
pyrophosphate deposition disease have identified muta-
tions in ANKH [86,87]. An early-onset form of this disease
with severe PGOA has been linked also to a region on
chromosome 8q [88].
Interactions between structural genes and
environment
In addition to specific structural gene mutations, well-
established risk factors for OA include trauma, aging,
obesity, and gender [89,90]. This raises the question of
whether OA caused by mutations in structural genes is
the result of changes in articular cartilage that are funda-
mentally very different from those that underlie the age-
related, obesity-related, or trauma-related disease. We do
not believe this is the case and argue that the clearly
defined genetic abnormalities in structural components of
articular cartilage result in OA simply because they lower
the threshold at which biomechanical stress on the joint
induces the cascade of cellular and molecular events that
define this disease. For example, mutations in the struc-
tural components of cartilage may alter matrix–cell interac-
tions and thereby cellular responses to cytokines, leading
to apoptosis and matrix destruction. Alternatively, the
chondrocyte response to mechanical stress in an abnor-
mal matrix structure may result in different patterns of
structural protein expression, dedifferentiation, hypertro-
phy, regeneration, and an abnormal pyrophosphate syn-
thesis [91]. In addition, mutations in structural genes may
lead to changes in molecular interactions between various
components of the extracellular matrix, altering the thick-
ness and three-dimensional organization of the cartilage
collagen fibrils and destabilizing the cartilaginous matrix
[92–94]. One of the curious features of OA associated
with mutations in genes encoding structural matrix pro-
teins is the selectivity with which different joints may be
affected. Thus, affected members of families with OA as a
result of mutations in COL9A2 show primarily knee OA,
while mutations in COL11A2 may affect hip joints. Since
collagens IX and XI are coexpressed with collagen II in the
articular cartilage of all joints, this joint selectivity is quite
puzzling. We suggest that the answer may be found in a
more careful examination of the interactions between
intrinsic and extrinsic factors that contribute to joint devel-
opment and function.
Extrinsic factors such as physical activity, occupation, and
trauma, along with intrinsic factors such as abnormal joint
alignment, joint hypermobility, decreased muscle strength,
and varus–valgus deformity, may alter the biomechanics
and loading stress conditions of various joints in different
ways [95] and play a critical role in the selection of geneti-
cally susceptible joints.
Conclusion
OA is a genetically complex disorder. Mutations in genes
encoding structural components of articular cartilage give
rise to rare forms of highly penetrant inherited diseases
that are associated with early-onset OA, whereas the
more common forms of the same disease that occurs with
increased frequency at an older age are associated with
genetic risk factors in the form of common population
polymorphisms. As more mutations in the structural genes
of articular cartilage are identified, careful clinical analyses
will be required to understand the genotype–phenotype
spectrum of these forms of hereditary OA. As with other
multifactorial diseases, the initiation, progression, and
severity of the OA disorder may be influenced by multiple
environmental, hormonal, and intrinsic and extrinsic
factors, with multiple genes in any given individual. The
identification of the genetic pathways will be difficult and
will represent a great challenge in the near future. Of criti-
cal importance are studies to understand the gene–gene
and gene–environment interactions, using animal models.
These efforts should provide a better understanding of the
pathogenesis of OA as well as a basis for developing
earlier preventive strategies and providing targets for the
development of new forms of treatment.
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